Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells

Cytotherapy

Volumn 14, Issue 9, 2012, Pages 1110-1118

  Knight, Andrea ^a   MacKinnon, Stephen ^a   Lowdell, Mark W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cytotoxicity; Flow cytometry; Gamma delta cells; Immunotherapy; Multiple myeloma

Indexed keywords

CD2 RECEPTOR; CD27 ANTIGEN; CD3 RECEPTOR; CD38 ANTIGEN; CD45RA ANTIGEN; DNAX ACCESSORY MOLECULE 1; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PHYTOHEMAGGLUTININ; PROTEIN; SYNDECAN 1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW BIOPSY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL ISOLATION; CELL KILLING; CELL SELECTION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; CYTOTOXICITY TEST; EX VIVO STUDY; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SORTING; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; VDELTA1 GAMMA DELTA T LYMPHOCYTE;

EID: 84866492925     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.700766     Document Type: Article

References (68)

1. Kaufmann SH. G amma/delta and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci USA. 1996; 93 : 2272 - 9.
2. Hayday AC. [gamma][delta] cells: A right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000; 18 : 975 - 1026.
3. Carding SR, E gan PJ. G ammadelta T cells: Functional plasticity and heterogeneity. Nat Rev Immunol. 2002; 2 : 336 - 45.
4. Pennington DJ, S ilva-Santos B, Hayday AC. G ammadelta T cell development: Having the strength to get there. Curr Opin Immunol. 2005; 17 : 108 - 15.
5. Kabelitz D., Wesch D, He W. P erspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007; 67 : 5 - 8.
6. Wrobel P, S hojaei H, S chittek B, G ieseler F, W ollenberg B, Kalthoff H, et al. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: Involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol. 2007; 66 : 320 - 8.
7. Gertner J, W iedemann A, P oupot M, F ournie JJ. Human gammadelta T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett. 2007; 110 : 42 - 53.
8. Bauer S, G roh V, W u J, S teinle A, P hillips JH, L anier LL, et a l. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999; 285 : 727 - 9.
9. Cerwenka A., Lanier LL. N KG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens. 2003; 61 : 335 - 43.
10. Cosman D, M ullberg J, S utherland CL, C hin W, A rmitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001; 14 : 123 - 33.
11. Scotet E, M artinez LO, G rant E, B arbaras R, J eno P, G uiraud M, et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity. 2005; 22 : 71 - 80.
12. Uchida R, A shihara E, S ato K, K imura S, K uroda J, T akeuchi M, et al. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun. 2007; 354 : 613 - 8.
13. Toutirais O, C abillic F, L e Friec G, S alot S, L oyer P, L e Gallo M, et al. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells. Eur J Immunol. 2009; 39 : 1361 - 8.
14. Lanca T., C orreia DV, Moita CF, R aquel H, Neves-Costa A, Ferreira C, et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood. 2010;115 : 2407 - 11.
15. Kong Y, Cao W, Xi X, Ma C, Cui L, He W. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood. 2009; 114 : 310 - 7.
16. Correia DV, F ogli M, H udspeth K, d a Silva MG, M avilio D, Silva-Santos B. Differentiation of human peripheral blood V{delta}1 - T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood. 2011; 118 : 992-1001.
17. von Lilienfeld-Toal M, N attermann J, F eldmann G, S ievers E, Frank S, Strehl J., et al. Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol. 2006; 144 : 528 - 33.
18. Kabelitz D., Holtmeier W. G ammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy. 2005; 86 : 151 - 83.
19. Xiong N., Raulet DH. D evelopment and selection of gammadelta T cells. Immunol Rev. 2007; 215 : 15 - 31.
20. Eberl M., J omaa H, H ayday AC. I ntegrated immune responses to infection: Cross-talk between human gammadelta T cells and dendritic cells. Immunology. 2004; 112 : 364 - 8.
21. D as H, W ang L, K amath A, B ukowski JF. V gamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood. 2001; 98 : 1616 - 8.
22. Clezardin P. B isphosphonates' antitumor activity: An unravelled side of a multifaceted drug class. Bone. 2011; 48 : 71 - 9.
23. Kunzmann VB auer E, F eurle J, W eissinger F, T ony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000; 96 : 384 - 92.
24. Wilhelm M, K unzmann V, E ckstein S, R eimer P, W eissinger F, Ruediger T., et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003; 102 : 200 - 6.
25. Corvaisier M, M oreau-Aubry A, D iez E, B ennouna J, Mosnier JF, Scotet E., et al. Vgamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol. 2005; 175: 5481-5488.
26. Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pintiere C, Daniel P. et al. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother. 2008; 57 : 531 - 9.
27. Abe Y, M uto M, N ieda M, N akagawa Y, N icol A, K aneko T, et al. Clinical and immunological evaluation of zoledronateactivated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol. 2009; 37 : 956 - 68.
28. D'Asaro M, L a Mendola C, D i Liberto D, O rlando V, Todaro M, Spina M, et al. Vgamma 9V delta 2 T lymphocytes effi ciently recognize and kill zoledronate-sensitized, imatinibsensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol. 2010 ; 184 : 3260 - 8.
29. Fulfaro F, C accamo N, M eraviglia S, Cicero G, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007 ; 67 : 7450 - 7.
30. Meraviglia S, E berl M, V ermijlen D, T odaro M, B uccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immuno therapy of advanced breast cancer patients. Clin Exp Immunol. 2010; 161 : 290 - 7.
31. Beck BH, K im HG, K im H, S amuel S, L iu Z, S hrestha R, et al. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res Treat. 2010; 122 : 135 - 44.
32. Bryant NL, G illespie GY, L opez RD, M arkert JM, C loud GA, Langford CP.et al. Preclinical evaluation of ex vivo expanded/ activated gammadelta T cells for immunotherapy of glioblastoma multiforme. J Neurooncol. 2011; 101 : 179 - 88.
33. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T., et al. Safety profi le and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: A pilot study. Cancer Immunol Immunother. 2007; 56 : 469 - 76.
34. Todaro M, D 'A saro M, C accamo N, I ovino F, F rancipane MG, Meraviglia S. et al. Effi cient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol. 2009; 182 : 7287 - 96.
35. Maeurer MJ, M artin D, W alter W, L iu K, Z itvogel L, Halusczcak K, et al. Human intestinal Vdelta1 - lymphocytes recognize tumor cells of epithelial origin. J Exp Med. 1996; 183 : 1681 - 96.
36. Choudhary A, D avodeau F, M oreau A, P eyrat MA, B onneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infi ltrating lymphocytes from renal carcinoma. J Immunol. 1995; 154 : 3932 - 40.
37. Halary F, P itard V, D lubek D, K rzysiek R, d e la Salle H, Merville P, et al. Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus- nfected cells and tumor intestinal epithelial cells. J Exp Med. 2005; 201 : 1567 - 78.
38. Dechanet J, M erville P, L im A, R etiere C, P itard V, Lafarge X, et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest. 1999; 103 : 1437 - 49.
39. Lafarge X, M erville P, C azin MC, B erge F, P otaux L, Moreau JF., et al. Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. J Infect Dis. 2001; 184 : 533 - 41.
40. Knight A, M adrigal AJ, G race S, S ivakumaran J, K ottaridis P, Mackinnon S., et al. The role of Vdelta2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood. 2010; 116 : 2164 - 72.
41. Godder KT, H enslee-Downey PJ, M ehta J. P ark BS, C hiang KY, Abhyankar S., et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007; 39 : 751 - 7.
42. Poggi A, V enturino C, C atellani S, C lavio M, M iglino M, Gobbi M, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 2004; 64 : 9172 - 9.
43. Lamb LS Jr, H enslee-Downey PJ, P arrish RS, G odder K, Thompson J, Lee C, et al. Increased frequency of TCR gamma delta - T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996; 5 : 503 - 9.
44. Catellani S, P oggi A, B ruzzone A, D adati P, R avetti JL, Gobbi M, et al. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood. 2007; 109 : 2078 - 85.
45. Sengupta N, MacFie TS, M acDonald TT, P ennington D, Silver AR. Cancer immunoediting and ' spontaneous ' tumor regression. Pathol Res Pract. 2010;206 : 1 - 8.
46. Girlanda S, Fortis C, Belloni D, Ferrero E., Ticozzi P, Sciorati C., et al. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined signifi cance plasma cells costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res. 2005; 65 : 7502 - 8.
47. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood. 2007; 110 : 921 - 7.
48. Guenther A, G ordon S, T iemann M, B urger R, B akker F, Green J.R, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer. 2010; 126 : 239 - 46.
49. C orso A., F erretti E, L azzarino M. Z oledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology. 2005; 10 : 215 - 24.
50. Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, et al. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011; 39 : 55 - 65.
51. Kondo M, S akuta K, N oguchi A, A riyoshi N, S ato K, S ato S, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 2008; 10 : 842 - 56.
52. B artkowiak J, K ulczyck-Wojdala D, B lonski JZ, R obak T. Molecular diversity of gammadelta T cells in peripheral blood from patients with B-cell chronic lymphocytic leukaemia. Neoplasma. 2002; 49 : 86 - 90.
53. Orsini DL, R es PC, V an Laar JM, M uller LM, S oprano AE, Kooy Y.M, et al. Asubset of V delta 1 - T cells proliferates in response to Epstein - Barr virus-transformed B cell lines in vitro. Scand J Immunol. 1993; 38 : 335 - 40.
54. Orsini DL, v an Gils M, K ooy YM, S truyk L, K lein G, v an den Elsen P, et al. Functional and molecular characterization of B cell-responsive V delta 1 - gamma delta T cells. Eur J Immunol. 1994; 24 : 3199 - 204.
55. Hacker G, Kromer S, Falk M, Heeg K, Wagner H, Pfeffer K. V delta 1 - subset of human gamma delta T cells responds to ligands expressed by EBV-infected Burkitt lymphoma cells and transformed B lymphocytes. J Immunol. 1992; 149 : 3984 - 9.
56. Peyrat MA, Netzer S, Dechanet-Merville J, Bonneville M, Scotet E. Upregulation of cytolytic functions of human V{delta}2neg {gamma}{delta} T lymphocytes through engagement of ILT2 expressed by tumor target cells. Blood. 2011; 117 : 2864 - 73.
57. Castella B, V itale C, C oscia M, M assaia M. V gamma9Vdelta2 T cell-based immunotherapy in hematological malignancies: From bench to bedside. Cell Mol Life Sci. 2011; 68 : 2419 - 32.
58. Meeh PF, K ing M, O'B rien RL, Muga S., Buckhalts P, Neuberg R, et al. Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother. 2006; 55 : 1072 - 80.
59. Siegers GM, D hamko H., Wang XH, M athieson AM, K osaka Y, Felizardo TC, et al. Human Vdelta1 gammadelta T cells expanded from peripheral blood exhibit specifi c cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy. 2011; 13 : 753 - 64.
60. Dolstra H, F redrix H, v an der Meer A, d e Witte T, F igdor C, van de Wiel-van Kemenade E. TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant. 2001; 27 : 1087 - 93.
61. Wang P., Malkovsky M. D ifferent roles of the CD2 and LFA-1 T-cell co-receptors for regulating cytotoxic, proliferative, and cytokine responses of human V gamma 9/V delta 2 T cells. Mol Med. 2000; 6 : 196 - 207.
62. Das H, Sugita M, B renner MB. M echanisms of Vdelta1 gammadelta T cell activation by microbial components. J Immunol. 2004; 172 : 6578 - 86.
63. Wesselborg S, J anssen O, P echhold K, K abelitz D. S elective activation of gamma/delta - T cell clones by single anti-CD2 antibodies. J Exp Med. 1991; 173 : 297 - 304.
64. Lopez RD, Xu S, Guo B, Negrin RS, Waller EK. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: Implications for the development of adoptive immunotherapy strategies. Blood. 2000; 96 : 3827 - 37.
65. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan A.W, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cellmediated killing of myeloma cells. Cancer Res. 2007; 67 : 8444 - 9.
66. Kunzmann V., Wilhelm M. A nti-lymphoma effect of gammadelta T cells. Leuk Lymphoma. 2005; 46 : 671 - 80.
67. Farag SS, C aligiuri MA. H uman natural killer cell development and biology. Blood Rev. 2006; 20 : 123 - 37.
68. Rohner A, L angenkamp U, S iegler U, K alberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res. 2007; 31 : 1393 - 402.